Gensight Biologics (LTS:0RIM) Total Tax Payable: €0.25 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0RIM Gensight Biologics SA LTS:0RIM
14 GF Score
Price €0.12
GF Value €0.04
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Gensight Biologics Total Tax Payable?

Gensight Biologics LTS:0RIM +11.92% 14 Total Tax Payable is €0.25 Mil as of Dec. 2025. GuruFocus rates LTS:0RIM with a GF Score™ of 14/100 and a GF Value™ of €0.04 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Gensight Biologics's Total Tax Payable for the quarter that ended in Dec. 2025 was €0.25 Mil.

Gensight Biologics's quarterly Total Tax Payable declined from Dec. 2024 (€0.17 Mil) to Jun. 2025 (€0.07 Mil) but then increased from Jun. 2025 (€0.07 Mil) to Dec. 2025 (€0.25 Mil).

Gensight Biologics's annual Total Tax Payable increased from Dec. 2023 (€0.03 Mil) to Dec. 2024 (€0.17 Mil) and increased from Dec. 2024 (€0.17 Mil) to Dec. 2025 (€0.25 Mil).

Gensight Biologics Total Tax Payable Related Terms

Gensight Biologics Total Tax Payable Historical Data

* Premium members only.

The historical data trend for Gensight Biologics's Total Tax Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gensight Biologics Total Tax Payable Chart

Gensight Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Tax Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.03 0.03 0.17 0.25

Gensight Biologics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Tax Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.02 0.17 0.07 0.25
LTS:0RIM
14GF Score
Gensight Biologics SA LTS:0RIM
Total Tax Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gensight Biologics Total Tax Payable Calculation

Total Tax Payable is the taxes liability owed to federal, state, and local tax authorities. It is the carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.

Frequently Asked Questions Learn more about Total Tax Payable →
What does a Total Tax Payable of €0.25 Mil mean?
Gensight Biologics (LTS:0RIM) has a Total Tax Payable of €0.25 Mil as of Dec. 2025. Tax Payable is the taxes liability owed to federal, state, and local tax authorities. View historical data on Gensight Biologics and its competitors.
Is Gensight Biologics' Total Tax Payable too high?
Gensight Biologics' current Total Tax Payable is €0.25 Mil. Overall, Gensight Biologics has a GF Score™ of 14/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gensight Biologics' Total Tax Payable compare to VRTX and REGN?
Gensight Biologics' Total Tax Payable of €0.25 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Tax Payable for a Biotechnology company?
A good Total Tax Payable depends on the Biotechnology industry context. However, Total Tax Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Tax Payable mean?
A high Total Tax Payable can signal that a stock is expensive relative to its fundamentals. Tax Payable is the taxes liability owed to federal, state, and local tax authorities. View historical data on Gensight Biologics and its competitors. Gensight Biologics's current Total Tax Payable is €0.25 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gensight Biologics stock overvalued right now?
Based on GuruFocus' analysis, Gensight Biologics (LTS:0RIM) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.04, compared to a current price of €0.12 — trading 191% above its estimated fair value. The current Total Tax Payable is €0.25 Mil. Gensight Biologics' overall GF Score™ is 14/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Tax Payable calculated?
Total Tax Payable is calculated from a company's financial statements. For Gensight Biologics (LTS:0RIM), the current Total Tax Payable is €0.25 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gensight Biologics (LTS:0RIM) Overvalued in 2026?

Based on GuruFocus' analysis, Gensight Biologics stock appears to be overvalued. The current stock price of €0.12 is trading 191% above its estimated GF Value™ of €0.04. GuruFocus considers Gensight Biologics to be Significantly Overvalued.

Key valuation signals for LTS:0RIM:

  • Total Tax Payable: €0.25 Mil
  • GF Value™: €0.04 vs. price of €0.12 (191% above fair value)
  • GF Score™: 14/100 with 8 warning signs

No single metric tells the full story. See the LTS:0RIM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gensight Biologics Business Description

Address 74, rue du Faubourg Saint-Antoine, Paris, FRA, 75012
Gensight Biologics SA is a clinical-stage biopharma company focused on developing and commercializing gene therapies for retinal neurodegenerative diseases and central nervous system disorders. The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. The product candidate, LUMEVOQ, was developed using the MTS technology platform and is designed to treat LHON by restoring the function of retinal diseases resulting from mutations.
14GF Score

Get the complete analysis for LTS:0RIM

Total Tax Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.12
Price
€0.04
GF Value